Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in Indiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 68 | 2,748 | 35% |
| 2020 | 59 | 2,289 | 39% |
| 2021 | 58 | 2,248 | 44% |
| 2022 | 59 | 2,252 | 47% |
| 2023 | 63 | 2,245 | 51% |
| 2024 | 65 | 2,274 | 53% |
| 2025 from claims | – | 2,169 1,991–2,295 | 54% |
| 2026 forecast | – | 2,183 1,921–2,519 | 55% |
| 2027 forecast | – | 2,190 1,872–2,609 | 55% |
| 2028 forecast | – | 2,196 1,832–2,688 | 56% |
| 2029 forecast | – | 2,201 1,798–2,760 | 57% |
| 2030 forecast | – | 2,206 1,767–2,827 | 57% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 31% of the cases CMS names in Indiana; 41 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 77% inpatient hospital, 23% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 90 | 3,677−2.1%/yr | −2.1%/yr | 3.2 | 1% | 4,120 in 2030+1.9%/yr |
| Illinois | 71 | 3,069−2%/yr | −2%/yr | 2.2 | 1% | 3,410 in 2030+1.8%/yr |
| Michigan | 60 | 2,354−6.6%/yr | −6.6%/yr | 2.7 | 2% | 2,220 in 2030−1%/yr |
| Missouri | 51 | 1,950−5.1%/yr | −5.1%/yr | 3.0 | 0% | 2,150 in 2030+1.6%/yr |
| Minnesota | 38 | 1,451−4.5%/yr | −4.5%/yr | 3.1 | 2% | 1,850 in 2030+4.1%/yr |
| Kansas | 34 | 1,416−0.7%/yr | −0.7%/yr | 3.4 | 6% | 1,630 in 2030+2.3%/yr |
| Iowa | 25 | 1,087+7%/yr | +7%/yr | 2.4 | 0% | 1,670 in 2030+7.4%/yr |
| Nebraska | 31 | 952+2%/yr | +2%/yr | 3.6 | 3% | 1,140 in 2030+3.1%/yr |
| Wisconsin | 22 | 934−3.1%/yr | −3.1%/yr | 1.6 | 5% | 1,390 in 2030+6.8%/yr |
| South Dakota | 15 | 545−0.8%/yr | −0.8%/yr | 4.1 | 0% | 660 in 2030+3.2%/yr |
| North Dakota | 7 | 286+1%/yr | +1%/yr | 2.8 | 0% | 250 in 2030−2.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 65 | 2,388−6%/yr | −6%/yr | 3.31.1× | 5% | 2,460 in 2030+0.5%/yr |
| Kyphoplasty & vertebroplasty | 13 | 1,180−9.3%/yr | −9.3%/yr | 1.61.2× | 19% | 1,300 in 2030+1.7%/yr |
| Cervical fusion & disc arthroplasty | 21 | 997−4.8%/yr | −4.8%/yr | 1.41.0× | 3% | 960 in 2030−0.6%/yr |
| SI joint fusion | 3 | 192+9%/yr | +9%/yr | 0.21.2× | 27% | 430 in 2030+14%/yr |
Lumbar fusion in every state, and its device makers · Every procedure market in Indiana · Every state · Compare with Ohio
Globus Medical leads with 30% of company spending on these surgeons in 2025, +13 pts on 2024.
In 2025, 22 companies reported engagement with Indiana’s surgeons worth $313K in consulting, speaking, meals and travel tied to these products, about $4,819 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.